Cytokeratin 18 Fragment Levels as a Noninvasive Biomarker for Nonalcoholic Steatohepatitis in Bariatric Surgery Patients

Clinical Gastroenterology and Hepatology

Volumn 6, Issue 11, 2008, Pages 1249-1254

  Diab, Dima L ^a   Yerian, Lisa ^a   Schauer, Philip ^a   Kashyap, Sangeeta R ^a   Lopez, Rocio ^a   Hazen, Stanley L ^a   Feldstein, Ariel E ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKERATIN 18;

ADULT; ARTICLE; BARIATRIC SURGERY; BLOOD LEVEL; CONTROLLED STUDY; DISEASE SEVERITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LIVER BIOPSY; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; MONITORING; MORBIDITY; NONALCOHOLIC FATTY LIVER; OBESITY; POSTOPERATIVE PERIOD; SENSITIVITY AND SPECIFICITY; SURGICAL PATIENT;

ADULT; BARIATRIC SURGERY; BIOLOGICAL MARKERS; BIOPSY; COHORT STUDIES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FATTY LIVER; FEMALE; HUMANS; KERATIN-18; LIVER; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; ROC CURVE; SENSITIVITY AND SPECIFICITY;

EID: 55149102644     PISSN: 15423565     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cgh.2008.07.016     Document Type: Article

References (27)

1. Angulo P. Nonalcoholic fatty liver disease. N Engl J Med 346 (2002) 1221-1231
2. Wieckowska A., and Feldstein A.E. Nonalcoholic fatty liver disease in the pediatric population: a review. Curr Opin Pediatr 17 (2005) 636-641
3. Machado M., Marques-Vidal P., and Cortez-Pinto H. Hepatic histology in obese patients undergoing bariatric surgery. J Hepatol 45 (2006) 600-606
4. Kroh M., Liu R., and Chand B. Laparoscopic bariatric surgery: what else are we uncovering?. liver pathology and preoperative indicators of advanced liver disease in morbidly obese patients. Surg Endosc 21 (2007) 1957-1960
5. Brunt E.M., and Tiniakos D.G. Pathological features of NASH. Front Biosci 10 (2005) 1475-1484
6. Adams L.A., Lymp J.F., St Sauver J., et al. The natural history of nonalcoholic fatty liver disease: a population-based cohort study. Gastroenterology 129 (2005) 113-121
7. Ekstedt M., Franzen L.E., Mathiesen U.L., et al. Long-term follow-up of patients with NAFLD and elevated liver enzymes. Hepatology 44 (2006) 865-873
8. Wieckowska A., McCullough A.J., and Feldstein A.E. Noninvasive diagnosis and monitoring of nonalcoholic steatohepatitis: present and future. Hepatology 46 (2007) 582-589
9. Angulo P. NAFLD, obesity, and bariatric surgery. Gastroenterology 130 (2006) 1848-1852
10. Mathurin P., Gonzalez F., Kerdraon O., et al. The evolution of severe steatosis after bariatric surgery is related to insulin resistance. Gastroenterology 130 (2006) 1617-1624
11. Feldstein A.E., and Gores G.J. Apoptosis in alcoholic and nonalcoholic steatohepatitis. Front Biosci 10 (2005) 3093-3099
12. Wieckowska A., Lopez A.R., Zein N.N., et al. Noninvasive assessment of hepatocyte apoptosis in nonalcoholic fatty liver disease: a multi-center validation study. Gastroenterology 132 (2007) A-729
13. Wieckowska A., Zein N.N., Yerian L.M., et al. In vivo assessment of liver cell apoptosis as a novel biomarker of disease severity in nonalcoholic fatty liver disease. Hepatology 44 (2006) 27-33
14. Kleiner D.E., Brunt E.M., Van Natta M., et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 41 (2005) 1313-1321
15. Friedman J.M. Obesity in the new millennium. Nature 404 (2000) 632-634
16. Machado M., and Cortez-Pinto H. Non-alcoholic steatohepatitis and metabolic syndrome. Curr Opin Clin Nutr Metab Care 9 (2006) 637-642
17. Marchesini G., Bugianesi E., Forlani G., et al. Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. Hepatology 37 (2003) 917-923
18. Haynes P., Liangpunsakul S., and Chalasani N. Nonalcoholic fatty liver disease in individuals with severe obesity. Clin Liver Dis 8 (2004) 535-547 viii
19. Collantes R., Ong J.P., and Younossi Z.M. Nonalcoholic fatty liver disease and the epidemic of obesity. Cleve Clin J Med 71 (2004) 657-664
20. Moretto M., Kupski C., Mottin C.C., et al. Hepatic steatosis in patients undergoing bariatric surgery and its relationship to body mass index and co-morbidities. Obes Surg 13 (2003) 622-624
21. Harnois F., Msika S., Sabate J.M., et al. Prevalence and predictive factors of non-alcoholic steatohepatitis (NASH) in morbidly obese patients undergoing bariatric surgery. Obes Surg 16 (2006) 183-188
22. Dallal R.M., Mattar S.G., Lord J.L., et al. Results of laparoscopic gastric bypass in patients with cirrhosis. Obes Surg 14 (2004) 47-53
23. Mattar S.G., Velcu L.M., Rabinovitz M., et al. Surgically-induced weight loss significantly improves nonalcoholic fatty liver disease and the metabolic syndrome. Ann Surg 242 (2005) 610-620
24. Feldstein A.E., Canbay A., Angulo P., et al. Hepatocyte apoptosis and fas expression are prominent features of human nonalcoholic steatohepatitis. Gastroenterology 125 (2003) 437-443
25. Feldstein A.E., Canbay A., Guicciardi M.E., et al. Diet associated hepatic steatosis sensitizes to Fas mediated liver injury in mice. J Hepatol 39 (2003) 978-983
26. Feldstein A.E., Werneburg N.W., Canbay A., et al. Free fatty acids promote hepatic lipotoxicity by stimulating TNF-alpha expression via a lysosomal pathway. Hepatology 40 (2004) 185-194
27. Feldstein A.E., Werneburg N.W., Li Z., et al. Bax inhibition protects against free fatty acid-induced lysosomal permeabilization. Am J Physiol Gastrointest Liver Physiol 290 (2006) G1339-G1346